207940.KS
207940.KS
KR7207940008
SAMSUNG BIOLOGICS
Loading chart...

Company Profile

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Related stocks

068270.KS
068270.KS • South Korea
Celltrion
179,600 KRW
30.56B USD 1Y +7.3%
CSL.AX
CSL.AX • Australia
CSL FPO [CSL]
183.84 AUD
61.65B USD 1Y -11.2%
0126Z0.KS
0126Z0.KS • South Korea
SAMSUNG EPIS HOLDINGS
340,500 KRW
6.32B USD
1801.HK
1801.HK • China
INNOVENT BIO
92.65 HKD
20.59B USD 1Y -2.6%
2269.HK
2269.HK • China
WUXI BIO
53.85 HKD
28.25B USD 1Y +31.5%
6990.HK
6990.HK • China
SKB BIO
444.6 HKD
13.54B USD 1Y -12.9%
196170.KQ
196170.KQ • South Korea
Alteogen
241,000 KRW
12.53B USD 1Y -33.6%
002821.SZ
002821.SZ • China
ASYMCHEM
177.93 CNY
9.64B USD 1Y +56.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
31.1% p.a.
Max Drawdown (5Y)
-38.0%
Sharpe Ratio (5Y)
-0.10
Beta Factor
0.19
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (31.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -57.3% in the extended horizon.
ende